Acer therapeutics plans nda submission for acer-001 in q3 2021 following pre-nda meeting with fda

Newton, mass. and geneva, switzerland, may 25, 2021 (globe newswire) -- acer therapeutics inc. (nasdaq: acer)(“acer”), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, and relief therapeutics holding ag (six: rlf, otcqb: rlftf)(“relief”), a biopharmaceutical company with its lead compound rlf-100tm (aviptadil) in advanced clinical development to treat severe covid-19 patients, today announced the outcome of acer's pre-new drug application (nda) meeting with the u.s. food and drug administration (fda) for acer-001 for the treatment of urea cycle disorders (ucds). acer-001 is a proprietary immediate release multi-particulate powder formulation of sodium phenylbutyrate (napb) with a taste-masked coating. acer-001 is being developed in collaboration with relief.
ACER Ratings Summary
ACER Quant Ranking